Dr. William T. Smith IV, MD
Cardiac Electrophysiology (Clinical Cardiac Electrophysiology Physician)
- Medicare participating
At a glance
- Medical school
- University of North Carolina at Chapel Hill School of Medicine (1996)
- Years since graduation
- 30
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 1,513
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1996Medical school: University of North Carolina at Chapel Hill School of Medicine
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Clinical Cardiac Electrophysiology Physician primary
NC license 9901325
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Novant Health New Hanover Regional Medical Center Wilmington, NC
- Novant Health Brunswick Medical Center Supply, NC
- Pender Memorial Hospital Burgaw, NC
- Columbus Regional Healthcare System Whiteville, NC
Medical groups
- Novant Health Medical Group Coastal Region LLC (599 clinicians)
- Novant Health New Hanover Regional Medical Center LLC (203 clinicians)
- Pender Memorial Hospital Incorporated (25 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 1,513
- Services billed
- 4,070
- Patients’ average age
- 78
| Service | Times | Patients |
|---|---|---|
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 454 | 345 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system or implantable defibrillator system, remote up to 90 days | 328 | 320 |
| Interrogation device evaluation(s), (remote) up to 30 days; implantable cardiovascular physiologic monitor system, implantable loop recorder system, or subcutaneous cardiac rhythm monitor system, remote data acquisition(s), receipt of transmissions and tec | 324 | 235 |
| Evaluation of cardiac rhythm monitor system, remote up to 30 days | 298 | 210 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system, remote up to 90 days | 229 | 223 |
| Established patient office or other outpatient visit, 30-39 minutes | 189 | 174 |
| Evaluation of implantable heart and blood vessel monitoring system, remote up to 30 days | 117 | 107 |
| Established patient office or other outpatient visit, 40-54 minutes | 116 | 109 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system | 114 | 109 |
| Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | 114 | 106 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Metoprolol Succinate Other prescribers in Wilmington, NC | 508 |
| Eliquis (apixaban) Other prescribers in Wilmington, NC | 456 |
| Metoprolol Tartrate Other prescribers in Wilmington, NC | 192 |
| Diltiazem 24hr Er (Cd) (diltiazem hcl) Other prescribers in Wilmington, NC | 148 |
| Sotalol (sotalol hcl) Other prescribers in Wilmington, NC | 145 |
| Furosemide Other prescribers in Wilmington, NC | 127 |
| Flecainide Acetate Other prescribers in Wilmington, NC | 125 |
| Losartan Potassium Other prescribers in Wilmington, NC | 117 |
| Amlodipine Besylate Other prescribers in Wilmington, NC | 105 |
| Amiodarone Hcl Other prescribers in Wilmington, NC | 93 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 9 companies reported 82 payments worth $5,536 in total to this clinician.
| Abbott Laboratories | $2,201 |
|---|---|
| Medtronic, Inc. | $2,099 |
| Boston Scientific Corporation | $749 |
| Philips North America LLC | $143 |
| Cook Medical LLC | $124 |
| Biosense Webster, Inc. | $117 |
| Atricure, Inc. | $60.76 |
| Biotronik Inc. | $21.66 |
| Food and Beverage | $3,246 |
|---|---|
| Travel and Lodging | $2,290 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Abbott Laboratories Aug 18, 2025 | Travel and Lodging AVEIR · Structural Heart · travel to Phoenix, AZ · in-kind | $943 |
| Medtronic, Inc. Feb 11, 2025 | Travel and Lodging travel to Chicago, IL · in-kind | $388 |
| Abbott Laboratories Aug 18, 2025 | Travel and Lodging AVEIR · Structural Heart · travel to Phoenix, AZ · in-kind | $256 |
| Medtronic, Inc. Mar 7, 2025 | Travel and Lodging travel to Chicago, IL · in-kind | $179 |
| Medtronic, Inc. Mar 8, 2025 | Travel and Lodging travel to Chicago, IL · in-kind | $179 |
| Medtronic, Inc. Mar 10, 2025 | Travel and Lodging travel to Chicago, IL · in-kind | $88.89 |
| Medtronic, Inc. Mar 8, 2025 | Travel and Lodging travel to Chicago, IL · in-kind | $72.67 |
| Abbott Laboratories Nov 13, 2025 | Travel and Lodging AVEIR · Structural Heart · travel to Phoenix, AZ · in-kind | $57.70 |
| Abbott Laboratories Oct 7, 2025 | Travel and Lodging AVEIR · Structural Heart · travel to Phoenix, AZ · in-kind | $54.16 |
| Medtronic, Inc. Mar 7, 2025 | Travel and Lodging travel to Chicago, IL · in-kind | $31.23 |
All 12 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| Abbott Laboratories Nov 13, 2025 | Travel and Lodging AVEIR · Structural Heart · travel to Phoenix, AZ · in-kind | $57.70 |
| Abbott Laboratories Oct 7, 2025 | Travel and Lodging AVEIR · Structural Heart · travel to Phoenix, AZ · in-kind | $54.16 |
| Abbott Laboratories Aug 18, 2025 | Travel and Lodging AVEIR · Structural Heart · travel to Phoenix, AZ · in-kind | $943 |
| Abbott Laboratories Aug 18, 2025 | Travel and Lodging AVEIR · Structural Heart · travel to Phoenix, AZ · in-kind | $256 |
| Abbott Laboratories Aug 18, 2025 | Travel and Lodging AVEIR · Structural Heart · travel to Phoenix, AZ · in-kind | $9.02 |
| Medtronic, Inc. Mar 10, 2025 | Travel and Lodging travel to Chicago, IL · in-kind | $88.89 |
| Medtronic, Inc. Mar 8, 2025 | Travel and Lodging travel to Chicago, IL · in-kind | $179 |
| Medtronic, Inc. Mar 8, 2025 | Travel and Lodging travel to Chicago, IL · in-kind | $72.67 |
| Medtronic, Inc. Mar 8, 2025 | Travel and Lodging travel to Chicago, IL · in-kind | $31.23 |
| Medtronic, Inc. Mar 7, 2025 | Travel and Lodging travel to Chicago, IL · in-kind | $179 |
| Medtronic, Inc. Mar 7, 2025 | Travel and Lodging travel to Chicago, IL · in-kind | $31.23 |
| Medtronic, Inc. Feb 11, 2025 | Travel and Lodging travel to Chicago, IL · in-kind | $388 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 5 industry-funded studies in 2025, from 1 companies. The companies reported $432,597 in research payments for these studies, mostly to the institutions running them.
- A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)
Eli Lilly and Company · Active, not recruiting · NCT06292013 - A Study of Orforglipron in Adult Participants With Obesity or Overweight and Type 2 Diabetes
Eli Lilly and Company · Completed · NCT05872620 - The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)
Eli Lilly and Company · Active, not recruiting · NCT06383390 - A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk
Eli Lilly and Company · Completed · NCT05803421 - Comparing the Extent to Which Three Different Formulations of LY4100511 (DC-853) Are Made Available in the Body, Alone and in the Presence of a Drug That Reduces Stomach Acid
Eli Lilly and Company · Terminated · NCT06916143
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.